Table 3.
Hazard Ratios for ER-positive breast cancer incidence in the tamoxifen arm according to side effects at 6 months and menopausal status.
| Side effect status | Overall |
Postmenopausal |
Premenopausal |
|||
|---|---|---|---|---|---|---|
| HR (95%CI) | P-value | HR (95%CI) | P-value | HR (95%CI) | P-value | |
| Hot flushes | ||||||
| No | Reference | Reference | Reference | |||
| Yes | 1.38 (1.04–1.85) | 0.03 | 1.81 (1.19–2.74) | 0.01 | 1.01 (0.66–1.55) | 0.96 |
| Vaginal discharge | ||||||
| No | Reference | Reference | Reference | |||
| Yes | 0.68 (0.43–1.06) | 0.09 | 0.64 (0.35–1.17) | 0.15 | 0.72 (0.36–1.44) | 0.35 |
| Vaginal dryness | ||||||
| No | Reference | Reference | Reference | |||
| Yes | 0.92 (0.55–1.54) | 0.75 | 0.84 (0.42–1.66) | 0.61 | 1.04 (0.45–2.26) | 0.92 |
HR = Hazard Ratio, CI = Confidence Interval.